Key result
Fenofibrate is linked to elevated serum creatinine, warranting routine renal monitoring within 1-2 months.
Case Report (n=6)
No
Fenofibrate, a fibric acid derivative, is used as adjunctive therapy with diet for treatment of hyperlipidemia. Side effects include gastrointestinal complaints and, rarely, elevations in liver function tests. According to the drug's package insert, elevations in serum creatinine may occur; although, no postmarketing case reports of fenofibrate-induced elevations in serum creatinine are on file with the manufacturer. Fenofibrate was the probable cause of elevations in serum creatinine concentrations in six patients at our clinic. As the implications of these elevations may be serious, routine serum creatinine monitoring is recommended at baseline and 1-2 months after starting fenofibrate.
No takes yet. Share an insight, caveat, or question.
Ritter et al. (2001) conducted a case report in Hyperlipidemia (n=6). Fenofibrate was evaluated on Elevation in serum creatinine concentrations. Fenofibrate was identified as the probable cause of elevated serum creatinine concentrations in 6 clinic patients, prompting a recommendation for routine monitoring at 1-2 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: